AlphaGenome 2: Deciphering how cells read DNA to better understand disease
Predicting how DNA sequences and their variations impact specific human cell types and disease.
via Google DeepMindReported by 2 outlets
Google DeepMind unveils AlphaGenome 2 to predict genetic variations across specific human cells
The story so far
AI summary of the reporting below · Updated · How we work
Google DeepMind announced AlphaGenome 2 on November 11, 2026, introducing an updated AI model that forecasts how DNA sequences and variations affect specific human cell types. Trained on more than 100 million individual cell profiles across 68 tissues, the system identifies nearly twice as many gene-expression-altering variants as its predecessor. AlphaGenome 2 is available immediately for non-commercial research through the AlphaGenome API and in a private preview for commercial users. [1][2]
Unlike the original model, which predicted properties across broad tissues simultaneously, AlphaGenome 2 operates conditionally. It evaluates one condition—such as a specific tissue, cell type, or state—alongside a million-letter DNA sequence at every stage of its architecture. The platform supports cross-modality imputation to predict missing experimental properties like chromatin accessibility from single measurements, and it adds predictions for DNA methylation alongside gene expression and histone modifications. [1]
Read the original reporting
2 outlets
Read at Google DeepMind
Google’s AlphaGenome 2 zooms in on the cellular roots of disease
Researchers at Google DeepMind have unveiled a new AI model designed to unravel how changes in our DNA affect different cells, giving scientists a more detailed view of a notoriously difficult problem that could hold important clues to the causes of disease - and point the way to new treatments. AlphaGenome 2 is the successor…
via The Verge